Private Equity
Andrea Alms Video: Money In Motion 102 - Deep Dive Immunotherapy Cancer Market Part 3
April 2024 - Private Equity
TRANSCRIPT Hello, my name is Andrea Alms. I'm technology investor and financial manager and this is your money in motion. On the last episode, we unveiled fifth and fourth biggest immuno therapy companies in the world. On this episode, we unveiled the top three. Let's review. The immunotherapy market size is 131.8 billion, with a 12.1% growth rate, and the category the largest market size US dollar amount. First place goes to whom you know therapy at again $131.8 billion market size and a distant second place is chemotherapy, bone marrow transplant, antigen, drug conjugate and radiation therapy. Review by market size. Immunotherapy drug market is segmented into monoclonal antibodies, immunomodulators, vaccine, and others is estimated. Monoclonal antibodies are about 42% of the immunotherapy drug market. Third place goes to Abbvie. Abbvie. The NYSE ticker is ABBV. It is a Chicago, Illinois based global pharmaceutical company. AbbVie's key immuno therapy drug is Imbruvica, which is a Buton tyrosine kinase inhibitor. It has been approved for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia, and Walden strong macro global bulimia as of April 1st, 2024, market cap 317.92 billion. As of year in 2023. Diluted earnings per share that's EPS trailing 12 months. TTM is $2.72. Revenue $54.50 $4.32 billion. Second place Merck is traded on the NYSE with the ticker of MRK. It is a Rahway, new Jersey based pharmaceutical company. The company's immunotherapy program is focused on the creation of checkpoint inhibitors and other types of immunotherapies. As of April 1st, 2023, market cap was 33 1.75 billion. As of year end 2023 EPS $0.14 revenue $60.12 billion. First place JNJ Johnson Johnson is traded on the NYSE. It is New Brunswick, new Jersey global pharmaceutical company. The company's key checkpoint inhibitor is called C T-cell, which is a Car T-cell therapy created for the treatment of multiple myeloma as of April 1st, 2024, market cap 380.22 billion. Year end 2023 EPS $5.21. Revenue 85.16 billion. Thank you. This is your money. Your money. in motion.